Forodesine
An investigational purine nucleoside phosphorylase inhibitor that disrupts the metabolism of deoxyguanosine in lymphoid cells, leading to selective death of malignant T-cells. It has been studied for the treatment of T-cell leukemia and lymphoma. This targeted mechanism offers a potentially more selective approach compared to conventional chemotherapy.
Moleküler Ağırlık
266,2500 g/mol
LogP
-2,30
TPSA
130,00 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.
2D Yapı
Cite this structure
Embed this structure
SMILES
O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12
InChI
InChI=1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1
Molecular Formula
C11H14N4O4
HBD / HBA
6 / 6
Döndürülebilir Bağlar
2
Ağır Atomlar
19
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
An investigational purine nucleoside phosphorylase inhibitor that disrupts the metabolism of deoxyguanosine in lymphoid cells, leading to selective death of malignant T-cells. It has been studied for the treatment of T-cell leukemia and lymphoma. This targeted mechanism offers a potentially more selective approach compared to conventional chemotherapy.
Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.
Yes, Forodesine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL218291. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 135409409. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="forodesine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/forodesine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/forodesine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/forodesine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="forodesine"></drugfyi-drug>